FIELD: medicine.
SUBSTANCE: invention concerns medicine and concerns treatment and prevention of tinnitus induced by excitotoxic cochlear injury. That is ensured by administration of the pharmaceutical composition in therapeutically effective amount that contains arylcycloalkylamine, being a selective antagonist of NMDA-receptor.
EFFECT: choice of the selective antagonist of NMDA-receptor from arylcycloalkylamine group in excitotoxic cochlear injury allows treating or preventing tinnitus without any detrimental effect on hearing.
9 cl, 2 ex, 7 dwg
Authors
Dates
2010-01-27—Published
2005-03-29—Filed